Novo Nordisk A/s Stock News

Cubist Systematic Strategies LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 75.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,892 shares of the companys stock after selling 27,268 shares during the period. Cubist Systematic Strategies LLCs holdings in []

The Immune Anti-Inhibitor Market report mainly studies the size, recent trends, and development status of the Immune Anti-Inhibitor market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain, and competitive landscape. Technological innovation and advancement

NEW ORLEANS, Nov. 19, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Dicerna Pharmaceuticals, Inc. (NasdaqGS: DRNA) to Novo Nordisk A/S (NYSE: NVO). Under the

The global Medical Needles market was valued at 5861.27 Million USD in 2020 and will grow with a CAGR of 4.08% from 2021 to 2027. Because of the need to avoid needle-stick injuries, the demand for hypodermic needles has skyrocketed.

Dicerna Pharmaceuticals, Inc. (DRNA) and Novo Nordisk (NVO) have signed an agreement under which Novo Nordisk will acquire Dicerna for $3. The post Dicerna Soars 78.7% on Novo Nordisks $3.3B Acquisition Offer appeared first on Smarter Analyst .

Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Dicerna Pharmaceuticals, Inc. Enters into a Definitive Agreement to be acquired by Novo Nordisk for USD3.3 Billion” Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) surged over 78% in premarket trading after Novo Nordisk entered into a definitive agreement to acquire the company for roughly 3.3 billion… The post “The Buzz” Show: Dicerna Pharmaceuticals (NASDAQ: DRNA) Acquisition by Novo Nordisk first appeared on Financial Buzz .

Dicernas liver targeted GalXC technology uses liver-targeted GalXC-based compounds to enable subcutaneous delivery of RNAi therapies designed to specifically bind to receptors on liver cells, leading to internalization and access to the RNAi machinery within the cells. A next-generation version of GalXC, called GHalXC-Plus, extended Dicernas capabilities in RNAi silencing to address tissues and organs outside the liver, while retaining key pharmacological features from GalXC. The post From R&D to M&A: Novo Nordisk to Acquire Dicerna for $3.3B appeared first on GEN - Genetic Engineering and Biotechnology News .

Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as Novo's strength lies in the metabolic disorder space

WILMINGTON, Del., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Dicerna Pharmaceuticals, Inc. (Dicerna) (NASDAQ GS: DRNA ) regarding possible breaches of fiduciary duties and other violations of law related to Dicernas agreement to be acquired by Novo Nordisk A/S. Under the terms of the agreement, Dicernas shareholders will receive $38.25 in cash for each share of Dicerna common stock they own.

NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by Novo Nordisk A/S (NYSE: NVO).

A juicy buyout offer from Novo Nordisk is giving Dicerna shareholders a big reason to cheer.

Wedbush Securities Inc. decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 39,259 shares of the companys stock after selling 461 shares during the quarter. Wedbush Securities Inc.s holdings in Novo Nordisk []

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) to Novo Nordisk for $38.25 per share in cash is fair to Dicerna shareholders. Halper Sadeh encourages Dicerna shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether D